Abstract library

35 results for "Sapp".
#2130 Remote Tracking of Symptoms, QoL and Wellbeing within the New Wales NET Service
Introduction: Patients with NETs have worse health-related quality of life (HRQoL) than the general population.
Technological advances have significantly increased electronic patient-reported outcome (ePRO) data collection capabilities.
There is little longitudinal PRO/ePRO data and limited data on gastrointestinal symptoms, particularly ‘diarrhoea’, in NET patients.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Mark Reynolds
#2901 Data is Power - Registry Experience at an ENETS COE
Introduction: The collection of anonymised data for patients with neuroendocrine tumours is necessary for the ongoing improvement of patient care and research/clinical trials.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Annette Hogg
Authors: Hogg A, Stell A, Marusic P, Sinnott R, ...
#973 Toward a Preoperative Classification of Mesenteric Lymph Node Metastases for Better Selection of Carcinoid Tumors Before Radical Surgery
Introduction: Surgery for small bowel carcinoid (SBC) and lymph node (LN) metastases, when technically possible, represents the best therapy. However, surgical challenge is (i) not to recuse patients for false unresectable mesenteric artery invasion, and/or (ii) to avoid extensive small bowel resection.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Surgical treatment
Presenting Author: MD PhD Reza Kianmanesh
#129 Grade according to Ki-67 or mitotic count in gastroenteropancreatic neuroendocrine tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (NETs) are uncommon tumors with a reported incidence of 2.5-5 per 100000 population. The recent classification system of NETs proposed by the European Neuroendocrine Tumor Society (ENETS) uses both Ki-67 labelling index and mitotic index to assign grade (low, intermediate, high). It has been adopted into routine practice but there is limited data on the relationship between these indices and their effect on classification.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#162 Different sites of rare metastases in neuroendocrine tumor patients detected by Ga-68 somatostatin receptor PET/CT
Introduction: The most common sites of metastases in neuroendocrine tumors are liver, lymph nodes, and bone.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Baum R P, ...
#366 Next Generation Sequencing is a Cost Effective and Time Saving Method in Clinical Genetic Screening of Patients with Pheochromocytomas
Introduction: Pheochromocytomas are rare tumours arising from adrenal medulla. Recent findings show that about 30-40% of pheochromocytomas are caused by germline mutations in one of the ten hereto known susceptibility genes: SDHA, SDHB, SDHC, SDHD, SDHAF2, RET, VHL, NF1, TMEM127 and MAD. This list of genes is constantly growing. These ten genes together consist of 128 exons and a genetic screening test is both extensive time-consuming and expensive. We introduce utilizing Next generation sequencing as a fast and cost effective method.
Conference:
Category: Basic
Presenting Author: Mr. Joakim Crona
#440 The First Neuroendocrine Tumor Methylome Using Methylation-Specific Immunoprecipitation Followed by Second Generation Sequencing – MeDIP-seq
Introduction: Recently, the first cancer methylomes have been created which identified differential methylation at CpG island-shores (2kb upstream of CpG islands) to be of particular importance in the tumourigenic process.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Christina Thirlwell
Authors: Thirlwell C, Sasmaz S, Dibra H, Feber A, ...
#457 Comparison of Transarterial Liver-Directed Therapies (LDT) for Low-Grade Metastatic Neuroendocrine Tumors (mNETs)
Introduction: Transarterial LDT can ameliorate symptoms and improve time to tumor progression (TTP) in mNETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Eric Engelman
#509 Activation of EGFR and c-Met Signaling Pathways in Well-Differentiated Neuroendocrine Tumors of the Small Intestine
Introduction: The biological mechanisms driving midgut carcinoid (MGC) are unknown. The purpose of this study is to explore the role of EGFR and c-Met signaling pathways in the pathogenesis.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Eric Liu
Authors: Liu E, Mikhitarian K, Revetta F, Shi C, ...
#744 Bio-Differentiating and Antiangiogenic Therapy with Gastroenteropancreatic Patients with Neuroendocrine Tumors (GEP-NETs)
Introduction: The outcome of patients with metastatic, progressive or recurrent neuroendocrine tumors remains poor despite the several novel therapeutic approaches.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Others
Presenting Author: MD Lubos Holubec
Authors: Holubec L, Finek J, Fiala O, Matejka V, ...